216 related articles for article (PubMed ID: 15262759)
1. Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma.
Smith RV; Goldman SY; Beitler JJ; Wadler SS
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):831-6. PubMed ID: 15262759
[TBL] [Abstract][Full Text] [Related]
2. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
[TBL] [Abstract][Full Text] [Related]
3. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.
Lee NY; de Arruda FF; Puri DR; Wolden SL; Narayana A; Mechalakos J; Venkatraman ES; Kraus D; Shaha A; Shah JP; Pfister DG; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):966-74. PubMed ID: 17145527
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma.
Spring PM; Valentino J; Arnold SM; Sloan D; Kenady D; Kudrimoti M; Haydon RC; Lee C; Given C; Mohiuddin M; Regine WF
Cancer; 2005 Oct; 104(8):1765-71. PubMed ID: 16149090
[TBL] [Abstract][Full Text] [Related]
6. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
Salama JK; Stenson KM; List MA; Mell LK; Maccracken E; Cohen EE; Blair E; Vokes EE; Haraf DJ
Arch Otolaryngol Head Neck Surg; 2008 Oct; 134(10):1060-5. PubMed ID: 18936351
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
Feng FY; Kim HM; Lyden TH; Haxer MJ; Feng M; Worden FP; Chepeha DB; Eisbruch A
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1289-98. PubMed ID: 17560051
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
10. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
Terhaard CH; Kal HB; Hordijk GJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
[TBL] [Abstract][Full Text] [Related]
11. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
Fung K; Lyden TH; Lee J; Urba SG; Worden F; Eisbruch A; Tsien C; Bradford CR; Chepeha DB; Hogikyan ND; Prince ME; Teknos TN; Wolf GT
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1395-9. PubMed ID: 16087298
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
[TBL] [Abstract][Full Text] [Related]
13. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
[TBL] [Abstract][Full Text] [Related]
14. IMRT in hypopharyngeal tumors.
Studer G; Lütolf UM; Davis JB; Glanzmann C
Strahlenther Onkol; 2006 Jun; 182(6):331-5. PubMed ID: 16703288
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma.
Doweck I; Robbins KT; Samant S; Vieira F
World J Surg Oncol; 2008 Jan; 6():2. PubMed ID: 18194553
[TBL] [Abstract][Full Text] [Related]
17. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
19. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.
Semrau R; Mueller RP; Stuetzer H; Staar S; Schroeder U; Guntinas-Lichius O; Kocher M; Eich HT; Dietz A; Flentje M; Rudat V; Volling P; Schroeder M; Eckel HE
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1308-16. PubMed ID: 16464538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
